Actavis Wins Verdict in Testosterone Replacement Trial

Actavis Inc. won a defense verdict in a heart attack case involving its Androderm testosterone replacement, as a federal jury in Illinois rejected a Minnesota man’s claims that the product was unsafe.

Brad Martin alleged Actavis improperly marketed Androderm for an age-related reduction in testosterone, rather than the endocrine disorder “classical” hypogonadism for which the Food and Drug Administration approved it.

A jury in the U.S. District Court for the Northern District of Illinois found for Actavis on claims alleging inadequate warning, design defect, negligence, breach of express warranty, and fraud.

Martin alleged he was prescribed Androderm, a skin patch, ...